University of Groningen
Treatment outcomes in ANCA-associated vasculitis
Hessels, Arno
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hessels, A. (2019). Treatment outcomes in ANCA-associated vasculitis: Determinants of efficacy and toxicity. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Treatment outcomes in
ANCA-associated vasculitis
Determinants of efficacy and toxicity
Arno Hessels
Treatment outcomes in ANCA-associated vasculitis: Determinants of efficacy and toxicity
Dissertation University of Groningen, The Netherlands Financial support by
the University of Groningen
University Medical Center Groningen
Graduate School for Drug Exploration (GUIDE) Vasculitis Stichting
are gratefully acknowledged.
ISBN:
978-94-6375-159-9 (printed version) 978-94-034-1493-5 (digital version) Cover design: Kristina Hristova Lay-out: Kristina Hristova
Printed by: Ridderprint B.V., Ridderkerk, the Netherlands
Further financial support for the printing of this thesis was kindly provided by Vifor Fresenius Medical Care Renal Pharma Ltd.
©A.C. Hessels 2018
All rights reserved. No part of this publication may be reproduced, copied, modified, stored in a retrieval system or transmitted without the prior permission in writing from the author.
Arno Christiaan Hessels
Treatment outcomes in
ANCA-associated vasculitis
Determinants of effi cacy and toxicity
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen
op gezag van de
rector magnifi cus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op woensdag 20 maart 2019 om 16:15 uur
door
geboren op 28 juli 1992 te Zwolle
Promotor Prof. dr. C. A. Stegeman Copromotores Dr. A. Rutgers Dr. J. S. F. Sanders Beoordelingscommissie
Prof. dr. T. van Gelder Prof. dr. T. P. Links Prof. dr. S. P. Berger
Introduction: current challenges in the treatment of ANCA-associated vasculitis
Pharmacogenetics
Review: gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis
Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11β-hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor
Characterizing treatment outcomes
Geographic diff erences in clinical presentation and outcome of antineutrophil cytoplasmic antibody-associated vasculitis: role of antibody specifi city
Azathioprine hypersensitivity syndrome in a cohort of antineutrophil cytoplasmic antibody-associated vasculitis patients
Leg muscle strength is reduced and is associated with physical quality of life in antineutrophil cytoplasmic antibody-associated vasculitis
Summary and future perspectives Nederlandse samenvatting Dankwoord
About the author Chapter 1
